Archive | The 100% Fund RSS for this section

C17 Research Network and 100% Fund Grant Competition — call for LOI [due 14-Dec-2018]

C17 is pleased to announce the call for LOI for the The 100% Fund C17 Grant Competition and Round 22 of the C17 Research Network Operating Grant Competition.

The C17 Operating Grant Competition is focused on multicenter, multidisciplinary pediatric oncology and hematology research.

The purpose of The 100% Fund Grant Competition is to target directly pediatric cancers that are rare and hard to treat—cancers that have not responded to available therapies. Applications addressing the hard-to-treat cancer types below will be considered for the fall 2018 100% Fund Grant Competition.

Please see the calls for LOI, LOI forms and C17 Award Guide documents, linked below.

The submission deadline for C17 LOIs is December 14, 2018 at 4 PM MST.

The application form and guidance document also can be downloaded from the C17 website (www.c17.ca) under Committees> Research Network.

Advertisements

STAY TUNED: Calls for LOI for the C17 Research Network Operating Grant and 100% Fund Grant Competitions are Expected Mid-November

The C17 Research Network anticipates announcing the calls for LOI for the following in mid/early November.

  • Operating Grant competition
  • 100% Fund competition – infant ALL
  • 100% Fund competition – rhabdomyosarcoma

Application forms specific to the competition will be uploaded; no significant changes are expected from the previous grant competition round.

Congratulations to Ted Gerstle from the Sick Kids Research Institute on the receipt of a 100% Fund grant targeting rhabdomyosarcoma

Grant title: MRI-guided High Intensity Focused Ultrasound-controlled hyperthermia to activate thermosensitive liposomal doxorubicin to treat rhabdomyosarcoma (RMS) in a mouse model

Lay abstract: Rhabdomyosarcoma (RMS), the most common muscle tumor of childhood, can be difficult to treat because of the side-effects of radiation and surgery in certain locations as well as the long term toxicity of chemotherapy agents. Magnetic Resonance Imaging (MRI) can be used to guide high intensity focused ultrasound (HIFU) beams to warm the tissue at the tumor up to a temperature of 42C. We will combine this mild hyperthermia with administration of an encapsulated chemotherapy drug (doxorubicin) specifically designed to release the drug in tissue which has been heated to 42C. We will create rhabdomyosarcoma tumors in mice and treat them using the combined MR guided HIFU and thermosensitivie doxorubicin formulation. We hypothesize that this combined approach could reduce tumor growth and minimize the toxicity of the drug by focusing its release at the tumor and minimizing systemic drug levels. This preclinical project would form the basis for the translation of the use of MRgHIFU and thermosensitive doxorubicin treatment into the pediatric oncology clinic, offering a treatment that could prolong life for patients with rhabdomyosarcoma and significantly reduce morbidity. This approach would be safer than current therapy and would be an exciting translation of MRgHIFU and liposomal doxorubicin from adult to pediatric therapy expanding treatment options for this challenging disease.

Funding partners: Fight Like Mason Foundation, Team Naomi, Team Finn and Coast-to-Coast Against Cancer. 100% Fund grants are adjudicated and administered by the C17 Research Network.


Nearly one in five children diagnosed with cancer will not survive. For children with rare and hard to treat cancers, the odds can be far worse. The 100% Fund has been created to challenge these odds. Coast-to-Coast Against Cancer is partnering with Phoebe Rose Rocks Foundation, Fight Like Mason Foundation, Team Naomi, and Team Finn to help fund research for children and teens who do not, yet, have their cure.  The purpose of The 100% Fund is to target directly pediatric cancers that are rare and hard to treat—cancers that have not responded to available therapies. Projects can range from discovery to clinical trials, but must be targeted at delivering a treatment intervention. The goal is to fund research with the potential to deliver improved treatment and increased survival rates.

Congratulations to Sumit Gupta from The Hospital for Sick Children on the receipt of a 100% Fund Grant targeting infant ALL

Grant title: The characterization of previously undetected MLL gene abnormalities in infant ALL

Lay Abstract: Infant acute lymphoblastic leukemia (ALL) is a rare, but devastating disease in babies less than 1 year old. For babies with high risk features, including an abnormality in the MLL gene (MLL-r), only one in five survive. Normally MLL-r is detected in a laboratory using FISH technology, the current standard. We encountered two babies who were found not to have MLL-r by FISH, but abnormalities were discovered using next generation sequencing (NGS), a newer technology. Identification of MLL-r is extremely important because studies show babies with high risk infant ALL have better outcomes using more intense therapy; failing to identify MLL-r may result in under-treatment. Also, new drugs have recently been developed targeting the MLL gene. If MLL-r is not detected, patients are not eligible for these potentially beneficial medications. We suspect that there are other infants with MLL-r that have not been detected by FISH. Using samples from patients with infant ALL and normal MLL genes by FISH, we will determine how often this happens by using NGS. If we find a significant number of hidden MLL-r, doctors will potentially have to change the way they detect such abnormalities so that patients receive appropriate therapy and optimal outcomes.

Funding partners:  Phoebe Rose Rocks and Coast-to-Coast Against Cancer. 100% Fund grants are adjudicated and administered by the C17 Research Network.


Nearly one in five children diagnosed with cancer will not survive. For children with rare and hard to treat cancers, the odds can be far worse. The 100% Fund has been created to challenge these odds. Coast-to-Coast Against Cancer is partnering with Phoebe Rose Rocks Foundation, Fight Like Mason Foundation, Team Naomi, and Team Finn to help fund research for children and teens who do not, yet, have their cure.  The purpose of The 100% Fund is to target directly pediatric cancers that are rare and hard to treat—cancers that have not responded to available therapies. Projects can range from discovery to clinical trials, but must be targeted at delivering a treatment intervention. The goal is to fund research with the potential to deliver improved treatment and increased survival rates.

C17 Call for LOI: The 100% Fund Grant Competition and the C17Operating Grant Competition

C17 is pleased to announce the inaugural round of The 100% Fund C17 Grant Competition and Round 21 of the C17 Research Network Operating Grant Competition.

The C17 Operating Grant Competition is focused on multicenter, multidisciplinary pediatric oncology/hematology research.

The purpose of The 100% Fund Grant Competition is to target directly pediatric cancers that are rare and hard to treat—cancers that have not responded to available therapies. Applications addressing the cancer types below will be considered for the fall 2017 competition.

In recognition of its 30th anniversary, Childhood Cancer Canada established The 100% Fund to challenge the odds for children and teens who do not, yet, have their cure.

Please see the calls for LOI, LOI forms and C17 Award Guide linked below. The application form and guidance document also can be downloaded from the C17 website (www.c17.ca/council-and-administrators/research/) under Committees> Research Network. The submission deadline for C17 LOIs is December 14, 2017 at 4 PM MST.

 

NEW C17 GRANT COMPETITION —The 100% Fund. Watch for a call for applications in the areas of infant ALL, rhabdomyosarcoma and Ewing sarcoma (click to read more!)

We are thrilled to announce a new C17 grant competition that will be run in addition to our regular C17 Operating Grant completion.  Watch for a call for Letters of Intent* this month!

Nearly one in five children diagnosed with cancer will not survive. For children with rare and hard to treat cancers, the odds can be far worse.

The 100% Fund has been created to challenge these odds. In recognition of its 30th anniversary, Childhood Cancer Canada (CCC) is proud to partner with organizations with a shared passion to help fund research for children who do not, yet, have their cure.   The list is growing, but confirmed organizations as of September 12th are:

By building on new and exciting research initiatives in Canada and around the world, The 100% Fund (www.the100pfund.ca) will pave the way for collaborative research into cutting-edge therapies for tumours that have not responded to currently available treatments.

CCC will partner with C17 Council and its C17 Research Network to administer the grants. As a national research organization representing leading pediatric oncology programs across Canada, the experts at the C17 know the priorities of children and their families that have been impacted by childhood cancer.

* Applications will include a full letter of intent with a 3 page research proposal.  Successful LOI will advance to the full grant application stage.  Applicants not funded in the funding round currently in progress will be able to submit to this upcoming competition.